|
US6312700B1
(en)
*
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
KR20000034847A
(ko)
*
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
|
ES2629683T3
(es)
|
1999-11-30 |
2017-08-14 |
Mayo Foundation For Medical Education And Research |
B7-H1, una nueva molécula inmunorreguladora
|
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
KR100468321B1
(ko)
*
|
2001-02-08 |
2005-01-27 |
학교법인 울산공업학원 |
종양 및 에이즈치료용 폴리펩타이드
|
|
EP1434596B1
(en)
*
|
2001-10-09 |
2009-07-08 |
Mayo Foundation For Medical Education And Research |
Enhancement of immune responses by agonist 4-1bb-antibodies
|
|
KR100452954B1
(ko)
*
|
2002-02-26 |
2004-10-14 |
주식회사 엘지생명과학 |
가변영역 아미노산 치환을 통한 인간 4-1비비분자에 대한결합 특이성이 증가된 변형 인간화 항체의 제조방법
|
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
EP1539929B1
(en)
*
|
2002-06-28 |
2013-04-10 |
Life Technologies Corporation |
Methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
CN1688603A
(zh)
*
|
2002-07-15 |
2005-10-26 |
马约医学教育与研究基金会 |
使用4－1bb结合剂的治疗和预防
|
|
US6887673B2
(en)
*
|
2002-07-30 |
2005-05-03 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1BB
|
|
AU2003290059A1
(en)
*
|
2002-12-16 |
2004-07-09 |
Herbert Schwarz |
Use of cd137 antagonists for the treatment of tumors
|
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
AR046094A1
(es)
*
|
2003-10-10 |
2005-11-23 |
Bristol Myers Squibb Co |
Anticuerpos completamente humanos contra 4-1bb humano
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
KR20050082389A
(ko)
*
|
2004-02-18 |
2005-08-23 |
메덱스젠 주식회사 |
직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
|
|
JP2007530588A
(ja)
|
2004-03-23 |
2007-11-01 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
レセプターカップリング剤およびその治療用途
|
|
US20070253961A1
(en)
*
|
2004-06-09 |
2007-11-01 |
Ulsan Industrial Education Foundation |
Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
|
|
EP1793857A4
(en)
*
|
2004-09-08 |
2008-09-03 |
Univ Ohio State Res Found |
COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES
|
|
JP5303146B2
(ja)
|
2004-10-06 |
2013-10-02 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
|
|
PT1817342E
(pt)
*
|
2004-12-02 |
2013-05-15 |
Bac Ip B V |
Método de purificação por afinidade
|
|
US20060182744A1
(en)
*
|
2005-02-15 |
2006-08-17 |
Strome Scott E |
Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
|
EP2399935A3
(en)
*
|
2005-02-15 |
2012-02-22 |
GTC Biotherapeutics, Inc. |
An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
|
US20080019905A9
(en)
*
|
2005-02-18 |
2008-01-24 |
Strome Scott E |
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
|
|
KR101507027B1
(ko)
*
|
2005-10-21 |
2015-03-31 |
엘에프비 유에스에이, 인크. |
항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
|
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
US20100015642A1
(en)
*
|
2006-01-05 |
2010-01-21 |
Kwon Eugene D |
B7-h1 and survivin in cancer
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
WO2009111315A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
US20120076722A1
(en)
*
|
2009-05-14 |
2012-03-29 |
University Of Maryland, Baltimore |
Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
|
|
ES2377785B2
(es)
|
2010-09-08 |
2012-09-26 |
Universidad Miguel Hernández De Elche |
Composición farmacéutica para el tratamiento del ojo seco.
|
|
JP6105470B2
(ja)
|
2010-09-09 |
2017-03-29 |
ファイザー・インク |
４−１ｂｂ結合分子
|
|
EP3536708A1
(en)
*
|
2011-04-19 |
2019-09-11 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
US20140234320A1
(en)
*
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
RU2493873C1
(ru)
*
|
2012-06-07 |
2013-09-27 |
Сергей Михайлович Юдин |
Инъекционный препарат для повышения спермопродукции у производителей сельскохозяйственных животных и петухов и способ его применения
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3470081A1
(en)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
CN105848680A
(zh)
|
2013-10-25 |
2016-08-10 |
药品循环有限责任公司 |
使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗
|
|
EP3066127A1
(en)
|
2013-11-06 |
2016-09-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
IL251669B2
(en)
|
2014-10-10 |
2023-02-01 |
Idera Pharmaceuticals Inc |
Cancer treatment using a tlr9 agonist with checkpoint inhibitors
|
|
KR102740444B1
(ko)
|
2015-04-17 |
2024-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
IL274151B
(en)
|
2015-05-21 |
2022-07-01 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
EP3943098A3
(en)
|
2015-07-16 |
2022-05-11 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP4019019B1
(en)
|
2016-05-20 |
2024-02-07 |
Biohaven Pharmaceutical Holding Company Ltd. |
Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
|
|
CN119060177A
(zh)
|
2016-05-20 |
2024-12-03 |
哈普恩治疗公司 |
单结构域血清白蛋白结合蛋白质
|
|
AU2017204125B1
(en)
|
2016-06-17 |
2017-10-26 |
Crispr Therapeutics Ag |
Compositions and methods for the depletion of cd117+ cells
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
IL268058B2
(en)
|
2017-01-20 |
2023-09-01 |
Magenta Therapeutics Inc |
Compositions and methods for depleting cd137 plus cells
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
CA3058175A1
(en)
|
2017-03-31 |
2018-10-04 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TW202500588A
(zh)
|
2017-04-13 |
2025-01-01 |
美商艾吉納斯公司 |
抗ｃｄ１３７抗體及其使用方法
|
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス，インク． |
メソテリン結合タンパク質
|
|
JP2020522516A
(ja)
|
2017-06-05 |
2020-07-30 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
|
|
KR20240147708A
(ko)
|
2017-07-11 |
2024-10-08 |
콤파스 테라퓨틱스 엘엘씨 |
인간 cd137에 결합하는 작동자 항체 및 이의 용도
|
|
MA49749A
(fr)
|
2017-08-01 |
2021-03-24 |
Lilly Co Eli |
Anticorps anti-cd137
|
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
EP3694529B1
(en)
|
2017-10-13 |
2024-06-26 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
JP2020536894A
(ja)
|
2017-10-15 |
2020-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
腫瘍処置法
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
SG11202004457XA
(en)
|
2017-11-17 |
2020-06-29 |
Iovance Biotherapeutics Inc |
Til expansion from fine needle aspirates and small biopsies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104289A1
(en)
|
2017-11-27 |
2019-05-31 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
EP3727463A1
(en)
|
2017-12-21 |
2020-10-28 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
WO2019136456A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
KR20200113228A
(ko)
*
|
2018-01-22 |
2020-10-06 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도
|
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
|
EA202092265A1
(ru)
|
2018-03-23 |
2020-12-24 |
Эли Лилли Энд Компани |
Антитела против cd137 для комбинации с антителами против pd-l1
|
|
WO2019183551A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
MD3775165T2
(ro)
|
2018-03-29 |
2024-09-30 |
Iovance Biotherapeutics Inc |
Procese de producție a limfocitelor infiltrante în tumori și utilizările acestora în imunoterapie
|
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
BR112020021660A2
(pt)
|
2018-04-27 |
2021-02-02 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, composição de criopreservação
|
|
US12473532B2
(en)
|
2018-05-10 |
2025-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
WO2020069028A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
EA202191175A1
(ru)
|
2018-10-29 |
2021-09-08 |
Мерсана Терапьютикс, Инк. |
Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
|
|
WO2020092736A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020096989A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
|
TW202039830A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
|
EP3877511A1
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
KR20210099573A
(ko)
|
2018-11-05 |
2021-08-12 |
이오반스 바이오테라퓨틱스, 인크. |
개선된 종양 반응성 t-세포의 선택
|
|
JP7710372B2
(ja)
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
|
MX2021011608A
(es)
|
2019-03-29 |
2021-12-10 |
Myst Therapeutics Llc |
Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
JP2022534981A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよび組み合わせ治療
|
|
EP3976832A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
KR20220016156A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
JP7749561B2
(ja)
|
2019-12-11 |
2025-10-06 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
|
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
BR112022016490A2
(pt)
|
2020-02-27 |
2022-10-11 |
Myst Therapeutics Llc |
Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas
|
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
JP2023524108A
(ja)
|
2020-05-04 |
2023-06-08 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
改良された腫瘍反応性ｔ細胞の選択
|
|
PH12022553153A1
(en)
|
2020-05-19 |
2024-02-26 |
Boehringer Ingelheim Int |
Binding molecules for the treatment of cancer
|
|
AU2021334361A1
(en)
|
2020-08-31 |
2023-05-11 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
US20240131064A1
(en)
|
2020-12-11 |
2024-04-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
EP4262811A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
US20220233689A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
DK4267105T3
(da)
|
2020-12-28 |
2025-05-19 |
Bristol Myers Squibb Co |
Antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
|
CA3207359A1
(en)
|
2021-02-05 |
2022-08-11 |
Cecile Chartier-Courtaud |
Adjuvant therapy for cancer
|
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
|
US20240376224A1
(en)
|
2021-04-02 |
2024-11-14 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
TW202308669A
(zh)
|
2021-04-19 |
2023-03-01 |
美商艾歐凡斯生物治療公司 |
嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
|
|
CA3219148A1
(en)
|
2021-05-17 |
2022-11-24 |
Frederick G. Vogt |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
US20250101380A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4493575A1
(en)
|
2022-03-18 |
2025-01-22 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
|
|
IL317319A
(en)
|
2022-06-02 |
2025-01-01 |
Bristol Myers Squibb Co |
Antibody compounds and methods of using them
|
|
US20260021181A1
(en)
|
2022-08-01 |
2026-01-22 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|